Septerna

Update in progress

SEPN (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Septerna, Inc. is a clinical‑stage biotech company that discovers and develops oral small‑molecule GPCR therapies for endocrinology, immunology/inflammation, and metabolic diseases. Programs include PTH1R agonists for hypoparathyroidism; SEP‑631, a MRGPRX2 NAM for chronic spontaneous urticaria and mast cell diseases; and a TSHR NAM for Graves’ disease and thyroid eye disease. It also explores neurology, women’s health, cardiovascular and respiratory areas. It has a global collaboration with Novo Nordisk for metabolic targets. Formerly GPCR NewCo, it renamed to Septerna in 2021 and is based in South San Francisco, CA.

Company score

Sentiment: 0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.06; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.03; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.03; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive